{
  "catalogId": "2dc009dc-1c93-4c1d-bed0-9b42b6aef95e",
  "name": "BRILINTA 60 MG",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "156 54 34752 00",
  "treatmentDescriptions": "Brilinta, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (ACS) or- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1).Limitations of use:  90 mg twice daily during the first year after an ACS event followed by 60 mg twice daily for additional 2 years.",
  "termsOfIssue": "Prescription required",
  "form": "film coated tablets",
  "route": "per os",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "TICAGRELOR",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "B01AC24",
      "name": "TICAGRELOR"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "BRILINTA 90MG 56TAB",
      "manufacturer": {
        "name": "אסטראזנקה",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 56.0,
        "unit": "units"
      },
      "packagingDescription": "BLISTER PVC/PVDC/ALUMINIUM",
      "shelfLife": "36",
      "storageConditions": "",
      "codes": {
        "moh": "6678",
        "yarpa": "15216",
        "pharmasoft": "2523"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 175.9030836,
        "retailMargin": 25.0,
        "maxRetailPrice": 219.8788545,
        "maxPriceWithVAT": 259.4570368
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-07-31T22:09:11.935496"
  }
}